The decision by Eli Lilly to resubmit lebrikizumab to the FDA for adults and adolescents with eczema is expected to receive a response in the second half of the year.
Alexis spoke in this AAD interview about his team’s results regarding lebrikizumab for adults and adolescents with moderate-to-severe atopic dermatitis and skin of color.
Elaine Siegfried, MD, of Saint Louis University School of Medicine discusses the use of biologics to treat atopic dermatitis (AD) and how they differ from other treatments.